Innoviva, Inc. (INVA)

Innoviva, Inc. (INVA) is a healthcare company (biotechnology) based in the United States. The share price is $18.35, up 0.25% on the day, which values the company at $1.3B. Price as of 18 Nov 2026, 18:19 UTC, from Yahoo Finance.

Key facts

Share price
$18.35+0.25% today
Market value
$1.3B
P/E ratio
7.8×last 12 months
Forward P/E
8.3×
Funk Score
61/100
Against its own history
Well below its usual priceof $27.77
200-week average
$17.664% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Innoviva, Inc. in more detail

INVA trades at 7.8× its last twelve months' earnings, 8.3× next year's expected earnings, 3.0× sales. Measured against its own history, the price is 34% below what its usual multiples would imply ($27.77) — well below its usual price. It sits 4% above its 200-week average of $17.66.

Over the last five fiscal years Innoviva, Inc. has compounded revenue 4.1% a year, earnings per share 10.3% a year, free cash flow -9.8% a year. Its Funk Score is 61 out of 100 (financial strength 7.3, profitability 7.2, growth 3.8, value 6.1, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Beneish M-score flags the accounts.

1 of the superinvestors tracked here hold INVA, including Chuck Royce (founder) (0.2% of the portfolio).

Superinvestors holding INVA

1 of the investors tracked here report a position in their latest 13F filing.

Innoviva, Inc. (INVA): questions and answers

What is INVA's P/E ratio?

Innoviva, Inc. trades at 7.8× its last twelve months' earnings and 8.3× next year's expected earnings. At its fiscal year-ends over the past 10 years the P/E ranged from 4.9× to 48.2×, with a median of 6.7×.

What is INVA's PEG ratio?

Innoviva, Inc.'s PEG ratio is 2.74 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Innoviva, Inc.'s market cap?

Innoviva, Inc. is valued at $1.3B at a share price of $18.35.

Is INVA overvalued or undervalued?

Against its own history, INVA is well below its usual price: the price is 34% below the $27.77 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is INVA above its 200-week moving average?

Yes. INVA is 3.8% above its 200-week average of $17.66. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Innoviva, Inc. growing?

Over the last five fiscal years Innoviva, Inc.'s revenue grew 4.1% a year and its earnings per share 10.3% a year; over ten years revenue grew 22.5% a year.

Cite this page

Funkfolio, “Innoviva, Inc. (INVA) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/INVA

Underlying data: Yahoo Finance; company filings with the SEC.